Monitor for actual execution of the option exercise and sale in upcoming days; while this is a routine transaction, the full exercise of both options may indicate reduced confidence in near-term upside or simply tax/estate planning. Given Rubin’s prior monthly sales of ~7,433 shares, this appears consistent with an ongoing strategy rather than a one-time exit signal.
BIOA drugs
BIOA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 1 $17.73entry
- T+1 · 8mo ago −1.30%α −1.38% · $17.50
- T+5 · 7mo ago +0.34%α −3.43% · $17.79
- T+20 · 7mo ago −4.91%α −14.63% · $16.86
- T+60 · 5mo ago +40.72%α +27.34% · $24.95
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Paul Rubin, an officer of BioAge Labs, filed a Form 144 notifying intent to sell up to 8,820 shares of common stock, exercisable via two stock options granted in 2020 and 2022, with the sale date reported as April 1, 2026. The filing reflects a planned exercise and sale of vested options, not an immediate large-scale disposition of existing holdings. Given the officer status and full exercise of available options, this signals moderate insider activity but is not unusually large in magnitude relative to market cap.
Key Facts
- Reporting owner: Paul Rubin, Officer of BioAge Labs, Inc.
- Number of shares intended for sale: 8,820 shares of common stock
- Shares to be acquired via exercise of two stock options: 5,437 shares (granted 07/01/2020) and 3,383 shares (granted 05/29/2022)
- Exercise method: Cash exercise
- Filing date: April 1, 2026
- Broker: Fidelity Brokerage Services LLC
- Market cap of BIOA: $776M
Financial Impact
Approximately 8,820 shares; based on prior monthly transactions (7,433 shares each month from Jan–Mar 2026) at average prices between $12.80–$20.00, estimated value of this proposed sale is ~$113,000–$176,000
Risk Factors
- Perception of insider selling could weigh on sentiment if market interprets this as lack of confidence
- Execution of the sale may result in minor near-term price pressure if completed in a short window
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001959173-26-002686 |
| Document: 0001959173-26-002686-index.html | 0001959173-26-002686 |
| Document: 0001959173-26-002686.txt | 0001959173-26-002686 |
Track record
11 reports on BIOA
2 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +13.00% at T+60 after the Apr 21, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $5.50 Now $5.22 −5.09% settles Nov 23
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $5.34 to $5.55 Now $5.22 −2.25% ▲ +3.93% +1.34% vs SPY
- Jun 16, 202621w ago Press Release Neutral 3/10 Entry $20.49 to $22.32 Now $5.22 −74.52% ▲ +8.93% +11.16% vs SPY
- May 8, 202627w ago 8-K Bullish 7/10 Entry $17.99 to $18.72 Now $5.22 −70.98% ▲ +4.03% +2.57% vs SPY
- Apr 21, 202629w ago DEFA14A Neutral 3/10 Entry $18.36 to $17.14 Now $5.22 −71.57% ▼ −6.64% −6.70% vs SPY
- Apr 21, 202629w ago Press Release Bullish 8/10 Entry $19.61 to $17.44 Now $5.22 −73.38% ▼ −11.07% −12.15% vs SPY
- Apr 1, 202632w ago 144 Neutral 3/10 Viewing Entry $17.73 to $17.79 Now $5.22 −70.56% ▲ +0.34% −3.43% vs SPY
- Mar 24, 202633w ago Press Release Mixed 6/10 Entry $16.11 to $17.49 Now $5.22 −67.60% ▲ +8.57% +8.99% vs SPY
- Mar 2, 202637w ago Court Ruling Bullish 7/10 Entry $20.46 to $20.97 Now $5.22 −74.49% ▲ +2.49% +2.96% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers